Skip to main content

Table 4 Base-case analysis results (per patient)

From: Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran

Strategy name

Total costs ($)

Total QALYs

ICER (Cost per QALY)

Incremental costs ($)

Incremental QALYs

MPH

695

0.557

0

0

0

LDX

750

0.765

264.28

54.9

0.208

  1. LDX Lisdexamfetamine, MPH Methylphenidate